Abstract 161P
Background
Targeted therapy and Immunotherapy have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC), particularly adenocarcinoma (AC). Among NSCLC cases, around 8-10% are ALK positive with the majority involving EML4-ALK gene variants. This study aims to explore the connection between ALK gene variants and PDL1 expression in metastatic lung AC, as there is limited data from the Indian cohort on this subject.
Methods
A retrospective analysis was conducted on data collected from 17 advanced lung AC patients with ALK gene mutations. The ALK protein variants were determined through Next-Generation Sequencing, while PDL1 expression was assessed using Immunohistochemistry with sP263 antibody. These findings were then correlated with relevant clinical parameters.
Results
The median age of the patient cohort was 46 years (range 28 to 65). Among the 17 ALK-positive, the majority had EML4-ALK gene fusions, with V1 (47.05%), V3 (35.2%), and V2 (11.7%) being the most common variants. V1 was more prevalent in females (87.5%) than males (12.5%). PDL1 negativity was observed in 64.7% of patients, while 35.2% were PDL1 positive. Specifically, PDL1 negativity was more common in the V1 variant, whereas PDL1 positivity was associated with V3. Brain metastases were more frequent in the PDL1-negative cohort (35.2%), and bone metastases and malignant pleural effusions were more common in V1 compared to V2 and V3. Table: 161P
ALK metastatic sites | Frequency |
Malignant pleural effusion | 70.5% |
Brain metastasis | 35.2% |
Bone metastasis | 35.2% |
Contralateral lung involvement | 23.5% |
Liver metastasis | 11.7% |
Conclusions
The study concludes that V1 and V3 EML4-ALK gene variants are prevalent in metastatic lung AC patients. It reveals a significant association between PDL1 expression and specific ALK variants, with V1 being more frequently associated with PDL1 negativity and V3 with PDL1 positivity. Additionally, the V1 and V3 variants were more commonly found in female patients and were associated with brain metastases. This real-world experience contributes valuable insights into treatment responses in this specific patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract